The uterus is a hollow organ, which is normally about the size and shape of a mediumsized pear. The uterus is where a fetus grows and develops when a woman is pregnant. The uterus has 2 main parts (see image below):
The body of the uterus has 2 main layers. The inner layer or lining is called the endometrium. The outer layer of muscle is known as the myometrium. This thick layer of muscle is needed to push the baby out during birth. The tissue coating the outside of the uterus is the serosa.
During a woman's menstrual cycle, hormones cause the endometrium to change. During the early part of the cycle, before the ovaries release an egg (ovulation), the ovaries produce hormones called estrogens. Estrogen causes the endometrium to thicken so that it could nourish an embryo if pregnancy occurs. If there is no pregnancy, estrogen is produced in lower amounts and more of the hormone called progesterone is made after ovulation. This prepares the innermost layer of the lining to shed. By the end of the cycle, the endometrial lining is shed from the uterus and becomes the menstrual flow (period). This cycle repeats until the woman's goes through menopause (change of life).
Types of cancers of the uterus and endometrium
The 2 main types of cancer of the uterus are:
Uterine sarcomas, which start in the muscle layer (myometrium) or supporting connective tissue of the uterus. These include uterine leiomyosarcomas and endometrial stromal sarcomas. These cancers are not covered here, but are discussed in detail in Uterine Sarcoma 2 .
q Endometrial carcinomas, which start in the cells of the inner lining of the uterus (the endometrium). Nearly all cancers of the uterus are this type. These cancers are the focus of the remainder of this information. Clear-cell carcinoma, mucinous adenocarcinoma, and papillary serous adenocarcinoma are less common types of endometrial adenocarcinomas. These types tend to be more aggressive than most endometrial cancers. They tend to grow quickly and often have spread outside the uterus at the time of diagnosis.
Grading endometrial carcinomas
The gradeof an endometrial cancer is based on how much the cancer forms glands that look similar to those found in normal, healthy endometrium.
In lower-grade cancers (grades 1 and 2), more of the cancerous tissue forms glands.
In higher-grade cancers (grade 3), more of the cancer cells are arranged in a haphazard or disorganized way and do not form glands. A small number of endometrial cancers are type 2 endometrial cancer . Type 2 cancers are more likely to grow and spread outside the uterus, they have a poorer outlook (than type 1 cancers). Doctors tend to treat these cancers more aggressively. They don't seem to be caused by too much estrogen. Type 2 cancers include all endometrial carcinomas that aren't type 1, such as papillary serous carcinoma, clearcell carcinoma, undifferentiated carcinoma, and grade 3 endometrioid carcinoma. These cancers don't look at all like normal endometrium and so are called poorly differentiated or high-grade.
Uterine carcinosarcoma (CS) starts in the endometrium and has features of both endometrial carcinoma and sarcoma. In the past, CS was considered a type of uterine sarcoma, but doctors now believe that CS is a carcinoma that is abnormal and so no longer looks much like the cells it came from (poorly differentiated).
Uterine CS is considered a type 2 endometrial carcinoma. CS tumors are also known as malignant mixed mesodermal tumors or malignant mixed mullerian tumors (MMMTs).
They make up about 4% of uterine cancers.
Cervical cancers
Cancers that start in the cervix and then spread to the body of the uterus are different from cancers that start in the body of the uterus; they are described in Cervical Cancer 4 .
Key Statistics for Endometrial Cancer How common is endometrial cancer?
In the United States, cancer of the endometrium is the most common cancer of the female reproductive organs. The American Cancer Society estimates for cancer of the uterus in the United States for 2019 are:
About 61,880 new cases of cancer of the body of the uterus (uterine body or corpus) will be diagnosed.
q About 12,160 women will die from cancers of the uterine body.
q These estimates include both endometrial cancers and uterine sarcomas. Up to 10% of uterine body cancers are sarcomas, so the actual numbers for endometrial cancer
What's New in Endometrial Cancer
Research and Treatment?
Molecular pathology of endometrial cancer
For several years we have known that damaged or defective DNA (mutations) can change important genes that control cell growth. If these genes are damaged, out-ofcontrol growth may result in cancer.
Sometimes, endometrial cancer and colon cancer 1 may seem to "run in a family." We now know that some of these families have a higher risk for these cancers because they have an inherited defect in certain genes that normally help repair damage to DNA.
If these repair enzymes are not working properly, damage to DNA is more likely to persist and cause cancer. Similar DNA repair defects have also been found in endometrial cancer cells from some patients without an inherited tendency to develop this disease. One of the normal genes responsible for suppressing tumor growth, called PTEN, is often abnormal in endometrial cancers.
Tests for this and other DNA changes may someday help find endometrial cancers early 2 . Endometrial cancers without other tumor suppressor genes (or with inactive ones), such as the retinoblastoma (Rb) gene and the TP53 gene, tend to be more likely to come back after initial treatment. Tests for these and other DNA changes may someday be used to help predict how aggressive the cancer might be and to select the best treatment for each woman with this disease. The long-range goal of this field of research is gene therapy that can correct the DNA abnormalities that caused the endometrial cells to become cancerous.
New treatments
New drugs, combinations of drugs and targeted therapies are being researched for use in women with advanced endometrial cancer. The use of adjuvant chemotherapy, with or without radiation is also being studied.
Targeted therapy
Researchers have been able to develop newer drugs that specifically target the gene and protein changes in cancer cells. These drugs work differently from standard chemotherapy (chemo) drugs. They often have different side effects. Some targeted therapies that are being studied to treat endometrial cancer include temsirolimus, bevacizumab, brivanib, and gefitinib.
Hormone therapy
Hormone therapy of endometrial cancer has often involved progestins, but drugs that affect estrogen may also be helpful. A recent study looked at using fulvestrant, a drug that blocks estrogen receptors.
Surgery
Another way to see if cancer has spread to the lymph nodes in the pelvis is to identify
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